Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Next Previous
Trial Profile

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emavusertib (Primary) ; Ibrutinib (Primary)
  • Indications Acute myeloid leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; CNS cancer; Diffuse large B cell lymphoma; Haematological malignancies; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms TakeAim Lymphoma
  • Sponsors Curis

Most Recent Events

  • 06 May 2025 According to a Curis media release, Company expect to provide additional data for both BTK-naive and BTK-experienced patients from the TakeAim Lymphoma study at ASH later in 2025.
  • 31 Mar 2025 According to a Curis media release, data update for 27 patients enrolled as of January 2, 2025 were published in a financial report.
  • 31 Mar 2025 According to a Curis media release, company successfully concluded meetings with both the U.S. Food and Drug Administration (FDA) and the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) on the suitability of using the ongoing TakeAim Lymphoma study (NCT 03328078) to support a potential accelerated approval path in PCNSL.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top